Tom Kornhauser1, Roy Schwartz2, Michaella Goldstein2, Meira Neudorfer2, Anat Loewenstein2, Adiel Barak2. 1. Department of Ophthalmology, The Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel. tomchook@gmail.com. 2. Tel Aviv Sourasky Medical Center and The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
PURPOSE: To assess the efficacy and safety of intraocular injections of bevacizumab in patients with macular edema (ME) following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). METHODS: Retrospective, non-comparative case series. Patients ≥18 years of age with ME secondary to BRVO or CRVO who received a minimum of one intravitreal injection of bevacizumab with a follow-up >3 months were included. Primary endpoints were mean change in best corrected visual acuity (BCVA) from baseline to 12 and 24 months, and mean change in central macular thickness (CMT) after 3 injections. Secondary endpoints were mean change in BCVA and CMT from baseline to end of follow-up, number of injections, and ocular adverse events. RESULTS: Eighty-seven eyes with BRVO and 65 eyes with CRVO were included. Mean follow-up time was 24.4 and 26.1 months in the BRVO and CRVO groups, respectively. The mean change in BCVA was 0.25 LogMAR in the BRVO group and -0.118 LogMAR in the CRVO group. CONCLUSION: Visual acuity outcomes in the CRVO group were poorer, especially in patients with low baseline BCVA.
PURPOSE: To assess the efficacy and safety of intraocular injections of bevacizumab in patients with macular edema (ME) following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). METHODS: Retrospective, non-comparative case series. Patients ≥18 years of age with ME secondary to BRVO or CRVO who received a minimum of one intravitreal injection of bevacizumab with a follow-up >3 months were included. Primary endpoints were mean change in best corrected visual acuity (BCVA) from baseline to 12 and 24 months, and mean change in central macular thickness (CMT) after 3 injections. Secondary endpoints were mean change in BCVA and CMT from baseline to end of follow-up, number of injections, and ocular adverse events. RESULTS: Eighty-seven eyes with BRVO and 65 eyes with CRVO were included. Mean follow-up time was 24.4 and 26.1 months in the BRVO and CRVO groups, respectively. The mean change in BCVA was 0.25 LogMAR in the BRVO group and -0.118 LogMAR in the CRVO group. CONCLUSION: Visual acuity outcomes in the CRVO group were poorer, especially in patients with low baseline BCVA.
Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079
Authors: David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2011-08 Impact factor: 12.079
Authors: Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2011-06-29 Impact factor: 12.079
Authors: David L Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta Journal: Ophthalmology Date: 2012-08-17 Impact factor: 12.079
Authors: Nikolaos T Voutsas; Eleni Papageorgiou; Alexandra Tantou; Vassilis A Dimitriou; Evangelia E Tsironi; Maria Kotoula Journal: Int Ophthalmol Date: 2022-04-13 Impact factor: 2.029
Authors: Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier Journal: Health Technol Assess Date: 2021-06 Impact factor: 4.014
Authors: Juan Lyn Ang; Sarah Ah-Moye; Leah N Kim; Vuong Nguyen; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Hemal Mehta Journal: Eye (Lond) Date: 2020-04-20 Impact factor: 3.775